P. Damiano
University of Malawi(MW)Faculdade São Leopoldo Mandic(BR)Sacmi (Italy)(IT)
Publications by Year
Research Areas
Atrial Fibrillation Management and Outcomes, Lung Cancer Treatments and Mutations, Antiplatelet Therapy and Cardiovascular Diseases, Cardiac Arrhythmias and Treatments, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives(2020)93 cited
- → Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study(2020)18 cited
- → PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors(2021)14 cited
- → Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial(2025)14 cited
- → Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC(2021)9 cited
- → Real-world evidence in extensive disease small cell lung cancer: The missing piece of the puzzle(2025)4 cited
- → PTEN loss as predictor of tumour heterogeneity (TH) and poor prognosis in EGFR-mutant advanced non-small cell lung cancer (ANSCLC) patients (pts) receiving tyrosine-kinase inhibitors (TKIs)(2019)
- → Dataset related to article "Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC "(2022)
- → Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCLC)(2019)
- → Robust, Quantile, and Mean Regression Diagnostics for a Comprehensive Analysis of Outlier Hemoglobin Levels in Women Using Cross-Sectional Survey Data in Malawi(2025)